Find an expert

Wendy Goodwin is a registered veterinarian in Queensland and has worked for the University of Queensland as a clinical anesthetist since 2010. She received her veterinary degree from the University of Queensland in 2004 and in 2013 was awarded a Doctorate of Philosophy by the University of Queensland for her research thesis ‘Studies of Alfaxalone in Horses’. In 2008 she was awarded Membership of the Australian & New Zealand College of Veterinary Scientists in Equine Medicine and in 2013 was awarded Membership in Veterinary Anaesthesia and Critical Care. In 2016 Wendy sucessfully became a Fellowship of the Australian & New Zealand College of Veterinary Scientists in Veterinary Anaesthesia and Critical Care.

Wendy is passionate about veterinary anaesthesia and analgesia and has dedicated the majority of her professional career to pursuing excellence in this field. Her clinical anaesthetic experience has covered a wide range of species including horses, small animal companion animals, farm animals, avian and exotic animals and animals used in scientific research. Wendy has a strong research interest and is keen to further explore research and development opportunities in the veterinary and medical sectors. She has papers published in peer reviewed scientific journals and presented her research findings at international conferences relating to veterinary anaesthesia and pain management.

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

• Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
• The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson’s disease pathophysiology
• Therapeutic targeting of the gut-brain axis for neuroprotection
• Drug discovery, development and repositioning for novel therapeutic targets
• Discovery and validation of clinical biomarkers for PD and ALS
• Clinical trials for disease-modifying therapeutic strategies

Dr Gordon’s research is focused on the formation and maintenance of the blood and lymphatic vascular systems. Vessels form complex branched networks that supply oxygen and nutrients to all body tissues. The signals controlling blood vessel expansion, identity and migration are all downstream of a single, common complex at the cell surface, yet exactly how this diverse range of functions is differentially regulated, depending on the physiological need, remains unknown.

The specific focus of Dr Gordon’s research is to determine the precise molecular signals that control cell adhesion within the vessel wall the surrounding environment. If the signals controlling cell adhesion become deregulated, normal vessel growth and function is lost. This contributes to the progression of a wide range of human diseases, including cancer growth and metastasis, diabetic eye disease and stroke. Dr Gordon aims to use novel biological models, biochemical assays and imaging techniques to better understand vessel biology, which will enable improved treatment of disease and aid in the development of vascularised, bioengineered organs.

Dr Gordon received her Bachelor of Science (2005) and PhD (2011) from The University of Adelaide, after which she undertook six years of postdoctoral studies at Yale University in the USA and Uppsala University in Sweden. With the support of an ARC DECRA Fellowship, Dr Gordon relocated to IMB in 2017 to establish her independent research career as an IMB Fellow. In 2019, she was appointed as Group Leader of the Vessel Dynamics Laboratory.

Professor Jürgen Götz (PhD, Dr. habil, FAHMS, GAICD) is Foundation Chair of Dementia Research, Director of the Clem Jones Centre for Ageing Dementia Research at the Queensland Brain Institute (University of Queensland), NHMRC Leadership Fellow and Ultrasound Team Leader. In 2023 he became the Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research. Jürgen Götz performed undergraduate studies at the Biocenter of the University of Basel, before joining the laboratory of Nobel Laureate Georges Köhler to obtain his PhD degree in immunology. Subsequently, he took up postdoctoral positions at UCSF (San Francisco) and Sandoz Ltd (now Novartis, Basel), and worked as Research Group Leader (venia legendi, Dr. habil.) at the University of Zurich (Switzerland). Before taking up his current position, Jürgen Götz was a Professor and Chair of Molecular Biology at the University of Sydney.

Jürgen Götz is a highly cited researcher (Clarivate) and an expert in basic and translational research in Alzheimer’s disease (AD), focusing on the cellular and molecular mechanisms of how Tau and Aβ cause neurodegeneration, using transgenic and cellular models, and exploring low-intensity ultrasound as a novel treatment modality for AD and other brain diseases (>220 publications, including in leading journals such as Science, Cell, Lancet and Neuron; h-index = 86, 27,800+ citations, Google Scholar). Jürgen Götz and his team have built a clinical trial-ready therapeutic ultrasound device and started a first-in-human safety trial in 12 Alzheimer patients (April 2023).

Hebe Gouda is an epidemiologist with research experience in Papua New Guinea, Indonesia and Egypt. She has a Masters of Public Health and a PhD from the University of Cambridge. She currently focuses on three related streams of research including: 1) Measuring mortality and disease burden with a particular focus on the epidemiological transition in low and middle income countries; 2) Evaluating health systems approaches and responses to population health burdens and 3) Measurement, data and information: the ethics and epistemology of population health research methods.

Frederick Graham (BNurs, PhD) is a Clinical Nurse Consultant and a Senior Research Fellow with the Centre for Health Services Research at the University of Queensland. As an academic-nurse, Fred is clinical lead of a hospital-wide Dementia and Delirium Nursing Service at Princess Alexandra Hospital where he has worked as clinical expert in the care of people with dementia and delirium for more than 15 years. As a senior research fellow under the mentorship of Professor Ruth Hubbard, his research focuses on reorganising care environments and building workforce capacity to provide therapeutic care to this vulnerable cohort with a specific focus on accelerating knowledge translation in managing symptoms of agitation through innovative experiential learning, models of care, environmental design, leisure activity, and recognition of pain-related symptomology.

Fred qualified as registered nurse from The Queensland University of Technology and has worked in acute-care wards at Princess Alexandra Hospital. He has clinically led multiple quality initiatives focussed on improving acute-care for patients with cognitive impairment including education and change champion initiatives, models of specialised care, resource development to facilitate person-centred care and development of a chart for evaluating analgesic trials through monitoring pain-related behaviour. These initiatives led Fred to undertake his PhD with Professor Elizabeth Beattie at QUT, titled “Do hospital nurses recognise pain in older agitated patients with cognitive impairment. A descriptive correlational study using virtual simulation.”, which was awarded QUT Outstanding Doctoral Thesis Award 2021. He has subsequently published his PhD results in the top gerontological and nursing journals in the world. Fred currently holds a Queensland Health Early Career Nursing Fellowship under the mentorship Professor Amanda Henderson, Nursing practice Development Unit PAH. He also has three Metro South Research Support Grant schemes including the Metro South Health Future Research Leader Fellowship under the mentorship of Professor Ruth Hubbard which will investigate pain-related phenotypes through a longitudinal response to treatment study.

As an emerging research leader and early career researcher, Fred is passionate teacher and encourages nurses to consider higher degree by research pathways in the clinical careers. He is currently supervising two higher research nursing students and a mentoring nurse practitioner student at UQ.

Dr Gratten completed his undergraduate studies and PhD at The University of Queensland, before undertaking postdoctoral training in evolutionary and quantitative genetics at the University of Sheffield. He then returned to Australia and shifted research focus to psychiatric and neurological genetics, taking up a position as research fellow at the Queensland Brain Institute. In 2013, he was recruited to UQ's Centre for Neurogenetics and Statistical Genomics, and in 2017 was awarded an NHMRC Career Development Fellowship (Level 2). He established the Cognitive Health Genomics group at Mater Research Institute in 2018, with the goal to improve understanding of the etiology of psychiatric and neurological disorders through analysis and integration of whole genome datasets. He has received >$5M in research funding from the NHMRC, Autism Cooperative Research Centre and both Australian (BICARE) and international (Brain & Behavior Research Foundation) philanthropic funders.

Professor Peter Gray is a pioneer of biotechnology research and development in Australia. In 2003 he was appointed AIBN’s inaugural Director and has since overseen the institute’s growth to 450 people and an annual turnover of $40million. Before joining AIBN, he was Professor and Head of Biotechnology at UNSW.

Professor Gray has held academic positions at University College London and the University of California, Berkeley. He has had commercial experience in the US, working for Eli Lilly and Co and the Cetus Corporation. His research collaborations include groups at Stanford University; the University of California, Berkeley; and the University of British Columbia, Vancouver.

He serves on several boards and government committees. He is on the board of Engineering Conferences International, New York, a group that runs global, multi-disciplinary engineering conferences, many of which have played key roles in developing emerging industry sectors. The conferences include cell culture engineering; vaccine technology; and scale-up and manufacturing of cell-based therapies. Professor Gray also serves on the board of Biopharmaceuticals Australia Pty Ltd, the company established to build a GMP grade biopharmaceuticals manufacturing facility in Brisbane, and has been heavily involved in negotiations that led to DSM Biologics becoming the facility’s operator.

Professor Gray is a Fellow and Vice-President of the Australian Academy of Technological Sciences and Engineering and a Fellow of the Australian Institute of Company Directors. He has chaired, served on organising committees for, and given plenary and keynote addresses at many key international conferences. In 2006 he attracted to Sydney and chaired the International Biotechnology Symposium – the first time a conference in the four-yearly series was held in the southern hemisphere. Professor Gray is a founder and past president of the Australian Biotechnology Association (Ausbiotech).

Professor Gray has graduated more than 60 PhD students from his research group, in fields including secondary metabolite bioprocesses; bioconversion of cellulosic substrates; mammalian cell expression of complex proteins; nanoparticles for drug delivery; and the development of stem-cell based bioprocesses. He has twice been listed by Engineers Australia among the top 100 most influential engineers in Australia, and in 2001 was awarded the Australian Government’s Centenary Medal.

Professor Gray is a Senior Researcher at the Centre for Health Services Research within the Faculty of Medicine.

He has formal training in medicine as a specialist geriatrician and in health administration. Previously he held senior management positions in the public health system in Victoria, in general management and aged care services. He joined academia full time at UQ in 2002. He directed the Centre for Health Services Research in its foundational period 2017-22. He now leads a vibrant research program that focuses on system level improvements within aged care.

His research interests focus on aged care policy, models of aged care service delivery, assessment and care planning systems, and in recent years, health informatics and telemedicine strategies.

He leads international development of hospital systems, and is a Board member and the Australian coordinator for interRAI, a multinational research collaborative.

Dr Christian Gray joined the Academy of Medical Education as a Senior Lecturer in 2019 and is a course coordinator and module lead. Prior to this, Dr Gray was a Lecturer in Infection and Immunity and was Immunology discipline lead at Peninsula Medical School at the University of Plymouth, Devon, UK.

Dr Gray has previously undertaken Postdoctoral research in a variety of areas in immunological research including therapies for rheumatoid arthritis, pneumococcal vaccines, mastitis resistance in dairy cattle, and vaccines for R. microplus. He obtained his PhD from the University of Newcastle, Australia in 2002. He was the first to identify a link between activation of regulatory T cells and the suppression of the immune system in patients with melanoma.

Within his current role he have transferred his skills from biomedical research into pedagogy of teaching and learning. He is actively developing a research portfolio within medical research focusing on the support of student learning.

Judith Greer is an immunologist with a strong interest in the nervous system and autoimmune diseases affecting the nervous system.

She is a graduate of the University of Queensland, having completed her PhD on cancer immunology. She then undertook postdoctoral training at Harvard Medical School in the USA, during which time her interests shifted towards immune responses and interactions within the nervous system (neuroimmunology), an area in which she has worked ever since. She isa Principal Research Fellow at the UQ Centre for Clinical Research, located at the Royal Brisbane & Women's Hospital.

Her research is directly particularly towards trying to identify brain components that are targetted by the immune system in people with a variety of disorders, particularly multiple sclerosis (MS), which is traditionally thought to be an autoimmune disease, but also in psychosis, where we are now starting to understand that autoimmune targetting of the brain can play a role in some patients. She is interested in how the specificity of autoimmune responses within the nervous system relates to the symptoms experienced by patients, and in developing new ways to specifically turn off the damaging immune responses in the brain. Another focus of her research is to improve on pre-clinical models of MS, so as to enhance the translation of new therapeutic approaches for MS to the clinic.

Judith is also interested in research training, and held leadership positions in this area in the School of Medicine and the Faculty of Medicine at UQ from 2000 - 2023. She is also committed to improving the field of neuroimmunology, and has been a member of the International Advisory Board of the International Society for Neuroimmunology and is the Asia-Pacific representative for the Global Schools of Neuroimmunology. Judith co-founded a society, Neuroimmunology Australia, to better support those working in this field, and was Convenor and Chair of the 14th International Congress of Neuroimmunology, which was held in Brisbane in 2018 (the only time this congress has been held outside of the Northern Hemisphere).

Ristan is an Honorary Associate Professor School of Medicine Southern Clinical School and MRI-UQ. Previously she has been Senior Biostatistician at Mater Research and Senior Lecturer in Epidemiology and Biosecurity with the School of Veterinary Science UQ. She is an epidemiologist, medical researcher and veterinarian who has been involved in medical and veterinary clinical research, academic teaching and veterinary practice for over 25 years. She completed her Bachelor of Arts majoring in Pure Mathematics in 1972, Bachelor of Veterinary Science in 1979, Master of Veterinary Science in 1995, PhD in the School of Medicine, The University of Queensland in 2004, and membership of the Epidemiology Chapter of the Australia and New Zealand College of Veterinary Scientists in 2005. Her areas of research interest include Congenital Hyperinsulinism of Infancy, bone metabolism in Cystic Fibrosis, Vitamin D in Type 1 Diabetes, as well as study design and data analysis. These latter interests have led to collaborations with clinicians and scientists in a wide variety of fields of research, for example human viral respiratory infection, paediatric liver disease, Pseudomonas spp infection in humans and horses, and many others. Since 1990, Dr Greer has been variously a lecturer and researcher with The University of Queensland School of Medicine, Queensland Children’s Medical Research Institute and affiliated institutions, and taught epidemiology in the School of Veterinary Science where she inaugurated the first course in research methodology for postgraduate students.

Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.

Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.

As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.

In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.

Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

I lead a research program with extensive expertise in immunology, particularly in natural killer (NK) cells, focused on developing innovative approaches for treating hard-to-cure diseases like metastatic cancers. Our mission is to improve patient outcomes and extend lives. My research group is based at the Translational Research Institute (TRI).

My dedication to my field has been recognized through numerous peer-reviwed grants as sole-CI or CIA/Principal Investigator, including a NHMRC ECF Peter Doherty Fellowship, an NHMRC Project Grant, an US DoD, a MRFF EMCR among others. Since 2009, I've amassed an impressive portfolio of 96 publications in renowned journals like Blood, Cell Death Dis, JEM, PNAS, Nat Comms, and Nat Immunol with an H-index = 40. My body of work and contributions have been acknowledged with awards such as the 2019 Researcher of the Year by CCA, 2020 QLD Young Tall Poppy Science, 2020 UQ Frazer Institute's Rising Star, 2022 Frazer Institute's Mentor of the Year, 2023 Translational Research Institute - Connecting with the Clinic among others. Recognized as an international leader in my field, I've been instrumental in identifying novel regulators of our immune functions, and developing NK cell-based immunotherapies.

At present, I am a Group Leader / Principal Research Fellow & Associate Professor with the University of Queensland's Frazer Institute. Here, I lead a high-performing research team with a keen focus on developing and innovating immunotherapy approaches for a spectrum of diseases.

Dr Karan Gulati is a Research Group Leader and the Deputy Director of Research at the School of Dentistry, UQ. He is also the Deputy Director of Centre for Orofacial Regeneration, Reconstruction and Rehabilitation (COR3) at UQ Dentistry.

Dr Gulati is a pioneer in electrochemically nano-engineered dental implants with over 13 years of extensive research experience using nano-engineering towards various bioactive and therapeutic applications. Dr Gulati completed his PhD from the University of Adelaide (Australia) in 2015 and was awarded the Dean’s Commendation for Doctoral Thesis Excellence. His career has been supported by prestigious fellowships from NHMRC (National Health and Medical Research Council, Australia), JSPS (Japan Society for the Promotion of Science, Japan), Erasmus+ (Germany) and the University of Queensland. At 8 years post-PhD, Dr Gulati has edited 3 books, published 7 chapters and >72 publications (h-index 35), and presented >110 times in various reputed conferences.

Completed specialist training in Endodontics in 2021 at the University of Adelaide and South Australian Dental Services. The DClinDent program included 9 articles in peer-reviewed journals, 1 article currently in press and one book chapter.

Completed a PhD which included 11 articles in peer-reviewed journals.

Completed the JBI Comprehensive systematic review training program.

Recipient of multiple research and travel grants.

Awarded a Fellow of the Pierre Fauchard Academy – an international dental association that recognizes and supports leaders of the dental profession.

Active researcher actively presenting research findings, locally and internationally, at scientific meetings as well as publishing multiple scientific articles.

Active contributor to dental teaching, research and philanthropy.

Committee member for the International Association of Dental Traumatology